Clinical trials: Acute Phase
Critical Illness
Effect of Combined IV Bolus Amino Acid Supplementation and Mobilisation on Skeletal Muscle During the First 10 Days in the ICU: A RCT
A single-centre, two-arm, parallel randomised controlled trial (RCT) to compare the combined effect of early intravenous bolus amino acid supplementation and mobilisation versus standard of care on changes in muscle mass over the…
- Trial name
- ProMob-ICU (NCT04099108)
- Testing
- Combined cycle ergometry and bolus amino acid supplementation
- Where
- South Africa
- Volunteers
- 50 people
- Sponsor
- University of Stellenbosch
Leukemia, Lymphoma
Interferon Alfa in Treating Children With HIV-Related Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's…
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00002621
- Testing
- recombinant interferon alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Children's Oncology Group
Trauma
Study to Evaluate Clinical Efficacy and Safety of "Medifoam H" in Wound Healing
The wound healing efficacy and safety of "Medifoam H" in patients with minor, acute trauma. The hypothesis of this study is that using "Medifoam H" dressing for a week is not inferior to using "Duoderm THIN" dressing in wound…
- Trial name
- Medifoam H (NCT01548443)
- Testing
- Medifoam H dressing, Duoderm THIN dressing
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Seoul St. Mary's Hospital
Acute Myeloid Leukemia
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for…
- Trial name
- NCT02560025
- Testing
- Alisertib, Cytarabine, Idarubicin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Acute Respiratory Distress Syndrome ARDS
Driving Pressure-guided Tidal Volume Ventilation in the Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is associated with high mortality, some of which can be attributed to ventilator-induced lung injury (VILI) when artificial ventilation is not customized to the severity of lung injury.
- Trial name
- DRIVENT (NCT06322758)
- Testing
- Tidal volume customization in the acute respiratory distress syndrome
- Volunteers
- 750 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Leukemia
Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents
The purpose of this study is to determine the maximum tolerable dose of irinotecan in combination with etoposide, cytarabine for refractory or relapsed acute leukemia in pediatric patient.
- Trial name
- NCT01239485
- Testing
- Irinotecan
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Seoul National University Hospital
Leukemia, Lymphoma
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol.
- Trial name
- NCT01200485
- Testing
- Rasburicase, Allopurinol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Ischemic Stroke
Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
The objective of this clinical trial was to explore the efficacy and safety of Y-3 injection at different doses in patients with acute ischemic stroke within 48 hours of onset.
- Trial name
- NCT06429384
- Testing
- Y-3 Injection/Y-3 blank injection
- Where
- 30 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing Tiantan Hospital
Acute Lung Injury, Acute Respiratory Distress Syndrome
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury
Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.
- Trial name
- UCMSC-ALI (NCT02444455)
- Testing
- UCMSC group
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Severe Acute Respiratory Syndrome Coronavirus 2
A Clinical Trial of COVAC-2 in Healthy Adults
VIDO has developed a vaccine called COVAC-2. The study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host…
- Trial name
- NCT04702178
- Testing
- COVAC-2
- Where
- 2 sites in Canada
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
aGVHD
A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation
To apply Ivarmacitinib for the prevention of acute graft-versus-host disease (aGVHD) in HLA haploidentical transplantation, the incidence of grade II-IV aGVHD after prevention, the incidence of primary graft failure, the rate of…
- Trial name
- Ivarmacitinib (NCT07381114)
- Testing
- Ivarmacitinib
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Trial name
- DHODH (NCT04609826)
- Testing
- JNJ-74856665, AZA, VEN
- Where
- 20 sites in France, South Korea and 2 more
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Acute-On-Chronic Liver Failure
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial
Liver disease deaths are rising, but transplants remain scarce in India. With over 100,000 needed annually and only ~2,500 performed, non-transplant options are urgently needed.
- Trial name
- NC-CHRM (NCT07075315)
- Testing
- Umbilical cord Mesenchymal stem cell, Steroid, Standard Medical Treatment
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) or mantle…
- Conditions
- Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03676504
- Testing
- CD19.CAR T Cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
Relapsed Adult AML
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
- Trial name
- NCT06613217
- Testing
- zelenirstat
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Pacylex Pharmaceuticals
Kidney Transplant, Rejection of Renal Transplant
Development and Validation of HistoMX, a Gene-Expression Platform for Molecular Interpretation of Kidney Allograft Biopsies
This retrospective multicentre observational study developed and validated HistoMX, an automated gene-expression-based platform for multidimensional molecular interpretation of kidney allograft biopsies.
- Conditions
- Kidney Transplant, Rejection of Renal Transplant, Antibody Mediated Rejection, BK Virus Nephropathy
- Trial name
- HistoMX (NCT07700563)
- Volunteers
- 2,410 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Acute Rheumatoid Arthritis
Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis
This is a proof of concept study asking if alkaline phosphatase injections can reduce acute inflammation in rheumatoid arthritis patients.
- Trial name
- ALS-003-2008 (NCT01416493)
- Testing
- s.c. injections of bovine intestinal Alkaline Phosphatase
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Alloksys Life Sciences B.V.
Acute Ischemic Stroke AIS
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
The study will evaluate the efficacy and safety of SIM0811 in participants with acute ischemic stroke who are present within 4.5 to 24 hours since last known well. The main questions it aims to answer are: 1.
- Trial name
- NCT07903701
- Testing
- SIM0811 Dose Level A (Phase II), SIM0811 Dose Level B (Phase II), SIM0811 Dose Level C (Phase II)
- Volunteers
- 1,092 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Acute Respiratory Distress Syndrome, Pneumonia
Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia
This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.
- Conditions
- Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection
- Trial name
- iGRASP (NCT02601365)
- Testing
- Sargramostim 0.04 mcg/kg/dose, Sargramostim 0.2mcg/kg/dose, Sargramostim 1 mcg/kg/dose
- Sponsor
- Milton S. Hershey Medical Center
Acute Kidney Injury, Sepsis
Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury
The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring dialysis who are in the…
- Trial name
- IRON-IC (NCT07236463)
- Testing
- Continuous veino-veinous dialysis with iron-chelator supplemented dialysate
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.